A Phase 2 interventional study of Pembrolizumab in Clear Cell Tumor, Gynecologic Cancer and Advanced Cancer, sponsored by University College, London. Completed at 5 sites in United Kingdom. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-22.
Sponsored by University College, London · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
PEACOCC is a multi-centre, single arm, single stage phase II trial. The overall aim is to determine whether treatment with pembrolizumab is effective in patients with advanced clear cell gynaecological cancer.
University College, London is the lead sponsor of 651 studies on the registry; 149 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
Counted across the registry records on this site, refreshed daily.
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumour sample. Some scores count stained tumour cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumour sample. Some scores count stained tumour cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pembrolizumab
3 weekly cycles of Pembrolizumab administered by IV
Progression Free Survival at 12 Weeks
The proportion of progression-free participants is defined as the number of participants alive with complete or partial response or stable disease maintained at 12 weeks (as assessed by the site radiologist and/or investigator, using RECIST v1.1) divided by the number of participants in the analysis population. Only participants with tumour assessment at or beyond 12 weeks were considered progression-free. All eligible participants who received at least one cycle of pembrolizumab were included in the analysis population. Any patient found to be ineligible will be excluded and replaced.
Time frame: 12 weeks
Progression-free Survival
All deaths were included, whether they occurred on study or following treatment discontinuation. For participants who had not died or progressed, progression-free survival were censored at the date of last contact.
Time frame: Time from start of trial treatment to progression or death from any cause (whichever came first).
Time to Second Disease Progression (Re-treatment Period)
Time to second disease progression refers to progression in participants re-treated on trial after their first progression. All deaths are included, whether they occur during the re-treatment period or following treatment discontinuation. For participants who have not died or progressed, second progression-free survival were censored at the date of last contact.
Time frame: Time from diagnosis of first progression during or after their initial pembrolizumab therapy to second progression or death from any cause (whichever came first), during or after their retreatment pembrolizumab.
Overall Survival
All deaths were included, whether they occurred on study or following treatment discontinuation. For participants who had not died, overall survival was censored at the date of last contact.
Time frame: Time from start of treatment to death from any cause.
Objective Response at 12 Weeks
Objective response is defined as a complete or partial response determined by RECIST v1.1. Participants without a tumour assessment at 12 weeks are considered to be non-responders.
Time frame: 12 weeks post start of treatment
Best Objective Response Rate
The best objective response rate consists of the best among all objective responses assessed. The analysis of best objective response was performed with all participants over the whole study period (including re-treatment phase).
Time frame: Time from start of treatment until last tumour assessment. Tumour imaging was performed at baseline, week 6, week 12 and then repeated every 12 weeks during trial treatment and follow-up; on average the last response assessment was at 12 weeks.
Duration of Response
For patients with an objective response, duration of objective response is defined as the time from initial complete or partial response to disease progression or death on study from any cause (defined as death within 110 days of the last study treatment), whichever occurs first. Participants were censored at the date of last contact.
Time frame: Time from initial complete or partial response to disease progression or death on study from any cause (defined as death within 110 days of the last study treatment), whichever occurred first.
Quality of Life (QoL): The Functional Assessment of Cancer Therapy - Ovarian (FACT-O) Total Score
The questionnaire used is The Functional Assessment of Cancer Therapy - Ovarian (FACT-O), version 4. Questionnaires were completed at baseline, week 6, week 12 and then repeated every 12 weeks during trial treatment and until progression/ end of treatment. The algorithm for core construction is based on that provided by the FACT-O manual using overall score. The higher the score, the better the QoL on a 0-152 scale (sum of physical, social, emotional and functional well-being); a negative score at end of treatment indicates a decrease in QoL from baseline.
Time frame: Change at end of treatment from baseline (before start of treatment), an average of 20 weeks.
Quality of Life (QoL): The Functional Assessment of Cancer Therapy - Ovarian (FACT-O) - Physical Well-being (PWB)
The questionnaire used is FACT-O (version 4). Questionnaires were completed at baseline, week 6, week 12 and then repeated every 12 weeks during trial treatment and until progression/ end of treatment. The algorithm for core construction is based on that provided by the FACT-O manual using overall sub-score. The higher the score, the better the QoL on a 0-28 scale; a negative score at end of treatment indicates a decrease in QoL from baseline.
Time frame: Change at end of treatment from baseline (before start of treatment), an average of 20 weeks.
Quality of Life (QoL): The Functional Assessment of Cancer Therapy - Ovarian (FACT-O) - Social Well-being (SWB)
The questionnaire used is FACT-O (version 4). Questionnaires were completed at baseline, week 6, week 12 and then repeated every 12 weeks during trial treatment and until progression/ end of treatment. The algorithm for core construction is based on that provided by the FACT-O manual using overall sub-score. The higher the score, the better the QoL on a 0-28 scale; a negative score at end of treatment indicates a decrease in QoL from baseline.
Time frame: Change at end of treatment from baseline (before start of treatment), an average of 20 weeks.
Quality of Life (QoL): The Functional Assessment of Cancer Therapy - Ovarian (FACT-O) - Emotional Well-being (EWB)
The questionnaire used is FACT-O (version 4). Questionnaires were completed at baseline, week 6, week 12 and then repeated every 12 weeks during trial treatment and until progression/ end of treatment. The algorithm for core construction is based on that provided by the FACT-O manual using overall sub-score. The higher the score, the better the QoL on a 0-24 scale; a negative score at end of treatment indicates a decrease in QoL from baseline.
Time frame: Change at end of treatment from baseline (before start of treatment), an average of 20 weeks.
Quality of Life (QoL): The Functional Assessment of Cancer Therapy - Ovarian (FACT-O) - Functional Well-being (FWB)
The questionnaire used is FACT-O (version 4). Questionnaires were completed at baseline, week 6, week 12 and then repeated every 12 weeks during trial treatment and until progression/ end of treatment. The algorithm for core construction is based on that provided by the FACT-O manual using overall sub-score. The higher the score, the better the QoL on a 0-28 scale; a negative score at end of treatment indicates a decrease in QoL from baseline.
Time frame: At end of treatment from baseline (before start of treatment), an average of 20 weeks.
Quality of Life (QoL): The Functional Assessment of Cancer Therapy - Ovarian (FACT-O) - Ovarian Cancer Sub-scale (OCS)
The questionnaire used is FACT-O (version 4). The algorithm for core construction is based on that provided by the FACT-O manual using overall sub-score. The higher the score, the better the QoL on a 0-100 scale (sum of PWB, FWB and OCS); a negative score at end of treatment indicates a decrease in QoL from baseline.
Time frame: Change at end of treatment from baseline (before start of treatment), an average of 20 weeks.
Potential participants were identified through routine clinics/multi disciplinary team meetings at the trial NHS Hospital research locations, or referral from external NHS Trust Consultant Oncologists. Patients were clinical screened for the trial and those who consented and were confirmed eligible by site investigator were registered by the Sponsor to enter the trial and start receiving trial treatment, pembrolizumab. The trial started recruiting patient
| Milestone | Pembrolizumab |
|---|---|
| Started | 48 |
| Completed | 48 |
| Not completed | 0 |
The proportion of progression-free participants is defined as the number of participants alive with complete or partial response or stable disease maintained at 12 weeks (as assessed by the site radiologist and/or investigator, using RECIST v1.1) divided by the number of participants in the analysis population. Only participants with tumour assessment at or beyond 12 weeks were considered progression-free. All eligible participants who received at least one cycle of pembrolizumab were included in the analysis population. Any patient found to be ineligible will be excluded and replaced.
| % of participants | Pembrolizumab |
|---|---|
| Progression Free Survival at 12 Weeks | 42 (28 to 57) |
All deaths were included, whether they occurred on study or following treatment discontinuation. For participants who had not died or progressed, progression-free survival were censored at the date of last contact.
| Months | Pembrolizumab |
|---|---|
| Progression-free Survival | 2.7 (1.3 to 5.4) |
Time to second disease progression refers to progression in participants re-treated on trial after their first progression. All deaths are included, whether they occur during the re-treatment period or following treatment discontinuation. For participants who have not died or progressed, second progression-free survival were censored at the date of last contact.
| Months | Pembrolizumab |
|---|---|
| Time to Second Disease Progression (Re-treatment Period) | 7.1 |
All deaths were included, whether they occurred on study or following treatment discontinuation. For participants who had not died, overall survival was censored at the date of last contact.
| Months | Pembrolizumab |
|---|---|
| Overall Survival | 14.8 (6.7 to 28.2) |
Objective response is defined as a complete or partial response determined by RECIST v1.1. Participants without a tumour assessment at 12 weeks are considered to be non-responders.
| % of participants | Pembrolizumab |
|---|---|
| Objective Response at 12 Weeks | 21 (10 to 35) |
The best objective response rate consists of the best among all objective responses assessed. The analysis of best objective response was performed with all participants over the whole study period (including re-treatment phase).
| % of participants | Pembrolizumab |
|---|---|
| Best Objective Response Rate | 25 (14 to 40) |
For patients with an objective response, duration of objective response is defined as the time from initial complete or partial response to disease progression or death on study from any cause (defined as death within 110 days of the last study treatment), whichever occurs first. Participants were censored at the date of last contact.
| Months | Pembrolizumab |
|---|---|
| Duration of Response | 13.1 (4.2 to 26.5) |
The questionnaire used is The Functional Assessment of Cancer Therapy - Ovarian (FACT-O), version 4. Questionnaires were completed at baseline, week 6, week 12 and then repeated every 12 weeks during trial treatment and until progression/ end of treatment. The algorithm for core construction is based on that provided by the FACT-O manual using overall score. The higher the score, the better the QoL on a 0-152 scale (sum of physical, social, emotional and functional well-being); a negative score at end of treatment indicates a decrease in QoL from baseline.
| FACT-O total score | Pembrolizumab |
|---|---|
| Quality of Life (QoL): The Functional Assessment of Cancer Therapy - Ovarian (FACT-O) Total Score | -6.7 ± 20.88 |
The questionnaire used is FACT-O (version 4). Questionnaires were completed at baseline, week 6, week 12 and then repeated every 12 weeks during trial treatment and until progression/ end of treatment. The algorithm for core construction is based on that provided by the FACT-O manual using overall sub-score. The higher the score, the better the QoL on a 0-28 scale; a negative score at end of treatment indicates a decrease in QoL from baseline.
| FACT-O score (PWB) | Pembrolizumab |
|---|---|
| Quality of Life (QoL): The Functional Assessment of Cancer Therapy - Ovarian (FACT-O) - Physical Well-being (PWB) | -1.3 ± 5.40 |
The questionnaire used is FACT-O (version 4). Questionnaires were completed at baseline, week 6, week 12 and then repeated every 12 weeks during trial treatment and until progression/ end of treatment. The algorithm for core construction is based on that provided by the FACT-O manual using overall sub-score. The higher the score, the better the QoL on a 0-28 scale; a negative score at end of treatment indicates a decrease in QoL from baseline.
| FACT-O score (SWB) | Pembrolizumab |
|---|---|
| Quality of Life (QoL): The Functional Assessment of Cancer Therapy - Ovarian (FACT-O) - Social Well-being (SWB) | -1.3 ± 3.43 |
The questionnaire used is FACT-O (version 4). Questionnaires were completed at baseline, week 6, week 12 and then repeated every 12 weeks during trial treatment and until progression/ end of treatment. The algorithm for core construction is based on that provided by the FACT-O manual using overall sub-score. The higher the score, the better the QoL on a 0-24 scale; a negative score at end of treatment indicates a decrease in QoL from baseline.
| FACT-O score (EWB) | Pembrolizumab |
|---|---|
| Quality of Life (QoL): The Functional Assessment of Cancer Therapy - Ovarian (FACT-O) - Emotional Well-being (EWB) | -0.3 ± 4.29 |
The questionnaire used is FACT-O (version 4). Questionnaires were completed at baseline, week 6, week 12 and then repeated every 12 weeks during trial treatment and until progression/ end of treatment. The algorithm for core construction is based on that provided by the FACT-O manual using overall sub-score. The higher the score, the better the QoL on a 0-28 scale; a negative score at end of treatment indicates a decrease in QoL from baseline.
| FACT-O score (FWB) | Pembrolizumab |
|---|---|
| Quality of Life (QoL): The Functional Assessment of Cancer Therapy - Ovarian (FACT-O) - Functional Well-being (FWB) | -1.8 ± 6.72 |
The questionnaire used is FACT-O (version 4). The algorithm for core construction is based on that provided by the FACT-O manual using overall sub-score. The higher the score, the better the QoL on a 0-100 scale (sum of PWB, FWB and OCS); a negative score at end of treatment indicates a decrease in QoL from baseline.
| FACT-O score (OCS) | Pembrolizumab |
|---|---|
| Quality of Life (QoL): The Functional Assessment of Cancer Therapy - Ovarian (FACT-O) - Ovarian Cancer Sub-scale (OCS) | -2.0 ± 7.87 |
Collected over All adverse events that occurred between informed consent and 30 days (or 110 for Adverse Events of Special Interest) post last trial treatment administration were collected, up to 2 years plus 30 days. Serious Adverse Events that occurred between informed consent and 110 days post last trial treatment administration (or after this date if the site investigator assessed the event as related to a trial treatment) were collected, up to 2 years plus 110 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pembrolizumab | 40/48 (83.3%) | 18/48 (37.5%) | 48/48 (100%) |
| Event | Pembrolizumab |
|---|---|
| FeverGeneral disorders | 3/48 |
| Abdominal painGastrointestinal disorders | 2/48 |
| Acute kidney injuryRenal and urinary disorders | 2/48 |
| Alanine aminotransferase increasedInvestigations | 2/48 |
| AscitesGastrointestinal disorders | 2/48 |
| Aspartate aminotransferase increasedInvestigations | 2/48 |
| DiarrhoeaGastrointestinal disorders | 2/48 |
| HypercalcaemiaMetabolism and nutrition disorders | 2/48 |
| HyperthyroidismEndocrine disorders | 2/48 |
| Lung InfectionInfections and infestations | 2/48 |
| Event | Pembrolizumab |
|---|---|
| fatigueGeneral disorders | 25/48 |
| nauseaGastrointestinal disorders | 24/48 |
| anorexiaMetabolism and nutrition disorders | 18/48 |
| abdominal painGastrointestinal disorders | 16/48 |
| constipationGastrointestinal disorders | 16/48 |
| diarrheaGastrointestinal disorders | 16/48 |
| hypertensionVascular disorders | 15/48 |
| painGeneral disorders | 14/48 |
| vomitingGastrointestinal disorders | 14/48 |
| back painMusculoskeletal and connective tissue disorders | 12/48 |
All trial participants who were registered and received at least one cycle of trial treatment were included in analysis.
| Age, Continuous(years) | Pembrolizumab |
|---|---|
| Median | 58.5 (32 to 77) |
| Sex: Female, Male(Participants) | Pembrolizumab |
|---|---|
| Female | 48 |
| Male | 0 |
| Race and Ethnicity Not Collected(Participants) | Pembrolizumab |
|---|
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2019 to primary completion in Jul 2024, 65 months.
Results were first posted in Sep 2026, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pembrolizumab